NasdaqGS:LXRX

Stock Analysis Report

Executive Summary

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products.

Snowflake

Fundamentals

High growth potential with worrying balance sheet.

Risks

  • Lexicon Pharmaceuticals has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Lexicon Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-10.5%

NasdaqGS:LXRX

-0.2%

US Biotechs

-1.0%

US Market


1 Year Return

-86.8%

NasdaqGS:LXRX

-8.1%

US Biotechs

-0.4%

US Market

LXRX underperformed the Biotechs industry which returned -10% over the past year.

LXRX underperformed the Market in United States of America which returned -1.7% over the past year.


Share holder returns

LXRXIndustryMarket
7 Day-10.5%-0.2%-1.0%
30 Day-74.4%-0.2%-3.3%
90 Day-77.9%2.4%0.4%
1 Year-86.8%-86.8%-7.3%-8.1%1.8%-0.4%
3 Year-91.1%-91.1%9.7%5.9%39.4%30.4%
5 Year-86.6%-86.6%7.8%2.8%54.2%37.1%

Price Volatility Vs. Market

How volatile is Lexicon Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Lexicon Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Lexicon Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Lexicon Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Lexicon Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

34.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Lexicon Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Lexicon Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.

Lexicon Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

Lexicon Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.

Lexicon Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Lexicon Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Lexicon Pharmaceuticals performed over the past 5 years?

-8.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Lexicon Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Lexicon Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Lexicon Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Lexicon Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Lexicon Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Lexicon Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Lexicon Pharmaceuticals's financial position?


Financial Position Analysis

Lexicon Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Lexicon Pharmaceuticals's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Lexicon Pharmaceuticals has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Lexicon Pharmaceuticals's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

Lexicon Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Lexicon Pharmaceuticals has less than a year of cash runway based on current free cash flow.

Lexicon Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 32.6% each year.


Next Steps

Dividend

What is Lexicon Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Lexicon Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Lexicon Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Lexicon Pharmaceuticals has not reported any payouts.

Unable to verify if Lexicon Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Lexicon Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Lexicon Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Lexicon Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

7.2yrs

Average management tenure


CEO

Lonnel Coats (54yo)

5.1yrs

Tenure

US$3,123,433

Compensation

Mr. Lonnel Coats has been the Chief Executive Officer and President of Lexicon Pharmaceuticals, Inc., since July 7, 2014. Mr. Coats served as an Executive Vice President, President of Americas Region at Ei ...


CEO Compensation Analysis

Lonnel's remuneration is higher than average for companies of similar size in United States of America.

Lonnel's compensation has increased whilst company is loss making.


Management Age and Tenure

7.2yrs

Average Tenure

59yo

Average Age

The average tenure for the Lexicon Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

12.0yrs

Average Tenure

64yo

Average Age

The average tenure for the Lexicon Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

More shares have been bought than sold by Lexicon Pharmaceuticals individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

BuyUS$11,40002 Aug 19
James Tessmer
EntityIndividual
Role
Vice President of Finance & Accounting
Shares10,000
Max PriceUS$1.14
BuyUS$28,20002 Aug 19
Samuel Barker
EntityIndividual
Role
Member of the Board of Directors
Shares24,000
Max PriceUS$1.18

Ownership Breakdown


Management Team

  • Kimberly Lee

    Head of Investor Relations & Corporate Strategy

  • Praveen Tyle (59yo)

    Executive Vice President of Research & Development

    • Tenure: 3.3yrs
    • Compensation: $1.46m
  • Chas Schultz

    Executive Director of Corporate Communications & Patient Advocacy

    • Tenure: 18.6yrs
  • Robert Lefkowitz (75yo)

    Consultant & Director

    • Tenure: 16.4yrs
    • Compensation: $96.22k
  • Lonnel Coats (54yo)

    President

    • Tenure: 5.1yrs
    • Compensation: $3.12m
  • Pablo Lapuerta (56yo)

    Executive VP & Chief Medical Officer

    • Tenure: 4.5yrs
    • Compensation: $1.26m
  • Alex Santini (60yo)

    Executive VP & Chief Commercial Officer

    • Tenure: 2.8yrs
    • Compensation: $1.23m
  • Brian Crum

    Vice President

  • James Tessmer (59yo)

    Vice President of Finance & Accounting

    • Tenure: 11.8yrs
    • Compensation: $508.34k
  • Jeffrey Wade (54yo)

    Executive VP of Corporate & Administrative Affairs and CFO

    • Tenure: 9.3yrs
    • Compensation: $1.41m

Board Members

  • Philippe Amouyal (60yo)

    Independent Director

    • Tenure: 12.0yrs
    • Compensation: $63.89k
  • Christopher Sobecki (60yo)

    Independent Director

    • Tenure: 12.0yrs
    • Compensation: $60.39k
  • Robert Lefkowitz (75yo)

    Consultant & Director

    • Tenure: 18.5yrs
    • Compensation: $96.22k
  • Lonnel Coats (54yo)

    President

    • Tenure: 5.1yrs
    • Compensation: $3.12m
  • Sam Barker (76yo)

    Independent Director

    • Tenure: 19.4yrs
    • Compensation: $69.39k
  • Judith Swain (70yo)

    Independent Director

    • Tenure: 11.9yrs
    • Compensation: $65.89k
  • Ray Debbane (64yo)

    Chairman of the Board

    • Tenure: 7.5yrs
    • Compensation: $80.39k
  • Alan Nies (81yo)

    Chairman of Medical Advisory Board & Independent Director

    • Tenure: 16.4yrs
    • Compensation: $137.05k
  • Frank Palantoni (62yo)

    Independent Director

    • Tenure: 14.8yrs
    • Compensation: $69.39k

Company Information

Lexicon Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lexicon Pharmaceuticals, Inc.
  • Ticker: LXRX
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$145.593m
  • Shares outstanding: 106.27m
  • Website: Click here

Number of Employees


Location

  • Lexicon Pharmaceuticals, Inc.
  • 8800 Technology Forest Place
  • The Woodlands
  • Texas
  • 77381
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LXRXNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDApr 2000
LX31DB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2000
LX31MUN (Boerse Muenchen)YesCommon SharesDEEURApr 2000

Biography

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/16 23:40
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.